Puengel, T.; Lefere, S.; Hundertmark, J.; Kohlhepp, M.; Penners, C.; Van de Velde, F.; Lapauw, B.; Hoorens, A.; Devisscher, L.; Geerts, A.;
et al. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. Int. J. Mol. Sci. 2022, 23, 6696.
https://doi.org/10.3390/ijms23126696
AMA Style
Puengel T, Lefere S, Hundertmark J, Kohlhepp M, Penners C, Van de Velde F, Lapauw B, Hoorens A, Devisscher L, Geerts A,
et al. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. International Journal of Molecular Sciences. 2022; 23(12):6696.
https://doi.org/10.3390/ijms23126696
Chicago/Turabian Style
Puengel, Tobias, Sander Lefere, Jana Hundertmark, Marlene Kohlhepp, Christian Penners, Frederique Van de Velde, Bruno Lapauw, Anne Hoorens, Lindsey Devisscher, Anja Geerts,
and et al. 2022. "Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis" International Journal of Molecular Sciences 23, no. 12: 6696.
https://doi.org/10.3390/ijms23126696
APA Style
Puengel, T., Lefere, S., Hundertmark, J., Kohlhepp, M., Penners, C., Van de Velde, F., Lapauw, B., Hoorens, A., Devisscher, L., Geerts, A., Boehm, S., Zhao, Q., Krupinski, J., Charles, E. D., Zinker, B., & Tacke, F.
(2022). Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. International Journal of Molecular Sciences, 23(12), 6696.
https://doi.org/10.3390/ijms23126696